[FOR RELEASE November 5, 2014 China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2014 --3Q14 Total Sales Up 29.5% to $68.9 Million / 9M Total Sales Up 15.2% to $185.3 Million-- --3Q14 Operating Margin Up 660 bp to 50.2% / 9M Operating Margin Up to 49.4% -- --3Q14 Non-GAAP Net Income Up 36.8% /] []
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
[Siu Ling Chan 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨ 3 SEC USE ONLY 4 SOURCE OF FUNDS PF 5 6 CITIZENSHIP OR PLACE OF ORGANIZATION People’s Republic of China NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1 2,367,581]
[Siu Ling Chan 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨ 3 SEC USE ONLY 4 SOURCE OF FUNDS PF 5 6 CITIZENSHIP OR PLACE OF ORGANIZATION People’s Republic of China NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1 2,367,581]
[FOR RELEASE November 3, 2014 China Biologic to Build Two New Plasma Collection Stations in Hebei Province BEIJING, China – November 3, 2014 – The new plasma collection stations will be located in Xinglong County of Chengde City and Daming County of Handan City. These two counties have a combined population of approximately one million. The Company intends to acquire] []
[FOR RELEASE November 3, 2014 China Biologic to Build Two New Plasma Collection Stations in Hebei Province BEIJING, China – November 3, 2014 – The new plasma collection stations will be located in Xinglong County of Chengde City and Daming County of Handan City. These two counties have a combined population of approximately one million. The Company intends to acquire] []
[Siu Ling Chan 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨ 3 SEC USE ONLY 4 SOURCE OF FUNDS PF 5 6 CITIZENSHIP OR PLACE OF ORGANIZATION People’s Republic of China NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1 2,686,010]
[FOR RELEASE September 4, 2014 China Biologic Completes Transaction to Acquire Additional Equity Stake in Guizhou Taibang BEIJING, China – September 4, 2014 – Additional information about this transaction can be found in the Company’s previous release and 8-K filing with the SEC on August 25, 2014. About China Biologic Products, Inc. China Biologic is a leading plasma-based biopharmaceutical company] []
[FOR RELEASE September 4, 2014 China Biologic Completes Transaction to Acquire Additional Equity Stake in Guizhou Taibang BEIJING, China – September 4, 2014 – Additional information about this transaction can be found in the Company’s previous release and 8-K filing with the SEC on August 25, 2014. About China Biologic Products, Inc. China Biologic is a leading plasma-based biopharmaceutical company] []
